{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:28:20Z","timestamp":1770978500528,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.ygyno.2008.06.028","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T11:38:54Z","timestamp":1220009934000},"page":"89-94","source":"Crossref","is-referenced-by-count":44,"title":["A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous \u00c56 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer"],"prefix":"10.1016","volume":"111","author":[{"given":"Sharad A.","family":"Ghamande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warner","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luceli","family":"Cuasay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidse O.","family":"W\u00fcrtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.06.028_bib1","first-page":"223","article-title":"CA 125 for the monitoring of ovarian carcinoma during primary therapy","volume":"69","author":"Lavin","year":"1987","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1023\/A:1008351216605","article-title":"Use of tumour markers in monitoring the course of ovarian cancer","volume":"10","author":"Rustin","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.ygyno.2008.06.028_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1634\/theoncologist.7-5-437","article-title":"CA125 response: can it replace the traditional response criteria in ovarian cancer?","volume":"7","author":"Guppy","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2008.06.028_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0002-9378(86)90077-3","article-title":"The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer","volume":"155","author":"Niloff","year":"1986","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a057754","article-title":"The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer","volume":"1","author":"Van der Burg","year":"1990","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib7","first-page":"53","article-title":"Ovarian cancer patients with high CA-125 but no symptoms\u2014should antiangiogenic treatments be considered?","volume":"9","author":"Sharma","year":"1997","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ygyno.2008.06.028_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1009095825561","article-title":"The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis","volume":"3","author":"Mazar","year":"1999","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ygyno.2008.06.028_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/hq0701.093685","article-title":"Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis","volume":"21","author":"Pepper","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib10","first-page":"2757","article-title":"Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy","volume":"7","author":"Harbeck","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2008.06.028_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000055086","article-title":"Clinical relevance of the plasminogen activator inhibitor type 1\u2014a multifaceted proteolytic factor","volume":"24","author":"Harbeck","year":"2001","journal-title":"Onkologie"},{"key":"10.1016\/j.ygyno.2008.06.028_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jnci\/93.12.913","article-title":"Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1","volume":"93","author":"Janicke","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2008.06.028_bib13","first-page":"1132","article-title":"Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer","volume":"8","author":"Riisbro","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2008.06.028_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1006\/gyno.2001.6324","article-title":"Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases","volume":"82","author":"Riisbro","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib15","first-page":"1843","article-title":"The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients","volume":"58","author":"Sier","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2008.06.028_bib16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1042\/bj3410765","article-title":"Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment","volume":"341","author":"Fishman","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.ygyno.2008.06.028_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/gyno.2000.5959","article-title":"Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometrial and endometrial carcinomas","volume":"79","author":"Foca","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1006\/gyno.2000.6015","article-title":"Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer","volume":"80","author":"Tecimer","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib19","doi-asserted-by":"crossref","first-page":"10647","DOI":"10.1073\/pnas.152127499","article-title":"Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer","volume":"99","author":"Memarzadeh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2008.06.028_bib20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/91.10.869","article-title":"Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis","volume":"91","author":"Stephens","year":"1999","journal-title":"J. Natl. Cancer. Inst."},{"key":"10.1016\/j.ygyno.2008.06.028_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2","article-title":"Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer","volume":"39","author":"Miyake","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.ygyno.2008.06.028_bib22","first-page":"879","article-title":"Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients","volume":"7","author":"McCabe","year":"2000","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2008.06.028_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1096\/fj.14.10.1400","article-title":"A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo","volume":"14","author":"Guo","year":"2000","journal-title":"FASEB. J."},{"key":"10.1016\/j.ygyno.2008.06.028_bib24","first-page":"4678","article-title":"An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer","volume":"62","author":"Guo","year":"2002","journal-title":"Cancer. Res."},{"key":"10.1016\/j.ygyno.2008.06.028_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0002-9440(10)63855-2","article-title":"A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis","volume":"162","author":"Boyd","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib26","doi-asserted-by":"crossref","first-page":"8484","DOI":"10.1073\/pnas.150239497","article-title":"A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin","volume":"97","author":"Mishima","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2008.06.028_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5414\/CPP42253","article-title":"Safety, tolerability, and pharmacokinetics of subcutaneous \u00c56, an 8-amino acid peptide with anti-angiogenic properties, in healthy men","volume":"42","author":"Van Troostenburg","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2008.06.028_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2005.05.023","article-title":"\u00c56, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer","volume":"99","author":"Berkenblit","year":"2005","journal-title":"A. phase I. trial Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer. Inst."},{"key":"10.1016\/j.ygyno.2008.06.028_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-8258(03)00051-9","article-title":"Clinical implications of rising serum CA 125 within normal range in patients with epithelial ovarian cancer: A preliminary investigation","volume":"89","author":"Wilder","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib31","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","article-title":"Risk of epithelial ovarian cancer recurrence in patients with rising CA 125 levels within the normal range","volume":"36","author":"Santillan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2008.06.028_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J. Natl. Cancer. Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800499X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800499X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T17:44:22Z","timestamp":1557769462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580800499X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S009082580800499X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.06.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}